# Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

> **NCT07717268** · PHASE2 · RECRUITING · sponsor: **Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic** · enrollment: 51 (estimated)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **DRUG:** Xtandi
- **DRUG:** Zytiga® (Abiraterone Acetate)
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT07717268
- **Lead sponsor:** Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-16
- **Primary completion:** 2030-05-16
- **Final completion:** 2030-05-16
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717268, "Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07717268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*